Network origin in Nicholas Vlahakis first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 5 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Nicholas Vlahakis via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ALZA CORPORATION | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal | |
| Washington University in St. Louis | College/University | Doctorate Degree | |
| PHARMACYCLICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Director/Board Member | |
Aerogen, Inc.
 Aerogen, Inc. Medical SpecialtiesHealth Technology Aerogen, Inc. develops and manufactures aerosol products for treatment of respiratory disorders in the critical care setting. Its products include Aerogen Solo, Aerogen Ultra, Aerogen Pro, Pro-C controller, and USB controller. The company is headquartered in Deerfield, IL. | Medical Specialties | Director/Board Member | |
| REVANCE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Stanford University | College/University | Corporate Officer/Principal | |
| The University of Manchester | College/University | Undergraduate Degree | |
Draupnir LLC
 Draupnir LLC Investment ManagersFinance Draupnir LLC (Draupnir) is a private equity firm founded in 2002 by Jeremy W. Hobbs. The firm is headquartered in Illinois, Chicago. | Investment Managers | Director/Board Member | |
| XENOPORT, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| DePaul University | College/University | Undergraduate Degree | |
| Knox College | College/University | Undergraduate Degree | |
| University of Illinois | College/University | Undergraduate Degree | |
| University of Kentucky | College/University | Doctorate Degree | |
Essex Woodlands Management, Inc.
 Essex Woodlands Management, Inc. Investment ManagersFinance Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas. | Investment Managers | Private Equity Investor | |
| CORIUM INTERNATIONAL INC | Pharmaceuticals: Major | Director/Board Member | |
| Harvard Medical School | College/University | Corporate Officer/Principal | |
| FLUENT, INC. | Data Processing Services | Investor Relations Contact | |
| PARNELL PHARMACEUTICALS HOLDINGS LTD | Pharmaceuticals: Major | Director/Board Member | |
| FIREBRICK PHARMA LIMITED | Pharmaceuticals: Major | Director/Board Member | |
| ALIGOS THERAPEUTICS, INC. | Pharmaceuticals: Major | Investor Relations Contact | |
Avestria Ventures Management, LLC
 Avestria Ventures Management, LLC Investment ManagersFinance Avestria Ventures Management LLC (Avestria Ventures) is a venture capital firm founded in 2018 by Linda M. Greub and Corinne H. Nevinny. The firm is headquartered in San Francisco, California. | Investment Managers | Consultant / Advisor | |
| ANEBULO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Université Paris-Saclay | College/University | Graduate Degree | |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| Aronex Pty Ltd. | Director/Board Member | ||
| Abio-X Holdings, Inc. | Investor Relations Contact | ||
| MIMEDX GROUP, INC. | Medical Specialties | Director/Board Member |
Statistics
International
| United States | 27 |
| Australia | 4 |
| United Kingdom | 2 |
| France | 2 |
Sectoral
| Health Technology | 16 |
| Consumer Services | 10 |
| Finance | 4 |
| Technology Services | 2 |
| Commercial Services | 2 |
Operational
| Director/Board Member | 13 |
| Independent Dir/Board Member | 5 |
| Corporate Officer/Principal | 5 |
| Chief Tech/Sci/R&D Officer | 5 |
| Undergraduate Degree | 4 |
Most connected contacts
| Insiders | |
|---|---|
| Phyllis Gardner | 19 |
| Kenneth Cundy | 6 |
| Jordyn Tarazi | 5 |
| Kent Grindstaff | 3 |
| Stephanie Tozzo | 3 |
- Stock Market
- Insiders
- Nicholas Vlahakis
- Company connections
